ReviewJournal of biomedicine & biotechnology2012
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE.
Review in Journal of biomedicine & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05045417 (IL17 in Systemic Lupus Erythematosus Patients), which is not on this map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage
Who cites it
81 citing papers in PubMed.
- Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.Scientific reports · 2016Trial
- An NT5E loss-of-function variant permits tissue inflammation and hypertension in systemic lupus erythematosus.iScience · 2026Article
- Review
- Immune effects of lipids isolated fromFrontiers in nutrition · 2026Article
- Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2025Article
- Exosomes derived let-7f-5p is a potential biomarker of SLE with anti-inflammatory function.Non-coding RNA research · 2025Article
- The Genetic Background of Ankylosing Spondylitis Reveals a Distinct Overlap with Autoimmune Diseases: A Systematic Review.Journal of clinical medicine · 2025Review
- Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025Review
- Curcumin versus triamcinolone acetonide gel in treating minor recurrent aphthous stomatitis: A randomized trial.Bioinformation · 2025Article
- Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus.bioRxiv : the preprint server for biology · 2024Article
- Inhibition of receptor interacting protein kinase-1 (RIPK1) in the treatment of murine lupus.Lupus science & medicine · 2024Article
- Non-thyroidal disease syndrome in patients with systemic lupus erythematosus: relation to disease inflammatory activity.Clinical rheumatology · 2024Article
- Effects of Lamiaceae family plants and their bioactive ingredients on coronavirus-induced lung inflammation.Food science & nutrition · 2024Review
- The impact of exogenous vasoactive intestinal polypeptide on inflammatory responses and mRNA expression of tight junction genes in lambs fed a high-grain diet.Journal of animal science · 2024Article
- Macrophage-Targeting DNA Nanomaterials: A Future Direction of Biological Therapy.International journal of nanomedicine · 2024Review
- Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis.International journal of molecular sciences · 2023Article
- Article
- Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans:International journal of molecular sciences · 2023Review
- Article
- Mesenchymal Stem Cells Suppress Dendritic Cells and Modulate Proinflammatory Milieu Through Interleukin-10 Expression in Peripheral Blood Mononuclear Cells of Human Systemic Lupus Erythematosus.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2023Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLE is an autoimmune inflammatory disease in which various pro- and anti-inflammatory cytokines, including TGF-β, IL-10, BAFF, IL-6, IFN-α, IFN-γ, IL-17, and IL-23, play crucial pathogenic roles. Virtually, all these cytokines can be generated by both innate and adaptive immune cells and exert different effects depending on specific local microenvironment. They can also interact with each other, forming a complex network to maintain delicate immune homeostasis. In this paper, we elaborate on the abnormal secretion and functions of these cytokines in SLE, analyze their potential pathogenic roles, and probe into the possibility of them being utilized as targets for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.